Nina Radosevic-Robin is an expert in Oncology at Centre Jean Perrin (France). Nina Radosevic-Robin has authored 100 publications, the most recent in 2025, and is an investigator in 7 clinical trials, 1 of them ongoing. SLR score: 312 (community average: 125). How the SLR is computed.

LeadR Profile

Nina Radosevic-Robin Centre Jean Perrin France
312 ScienceLeadR Reputation 312
Network Map

Oncology

Subspecialties:

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2011 - 2025

Source: PubMed

Centre Jean Perrin

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 100

Citations

Citations: 3 384 1st author: 10 Last author: 21 Unique author: 0


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Identification of serum proteins associated with response of triple-negative breast cancer to neoadjuvant chemotherapy: preliminary results from the INSTIGO trial.
PMID 41462069 — triple negative breast neoplasms, serum, breast neoplasms, neoplasms, drug therapy, biomarkers, breast, chemotherapy
Clin Proteomics20250
Comparison of the Predictive and Prognostic Capacities of Neutrophil, Lymphocyte and Platelet Counts and Tumor-infiltrating Lymphocytes in Triple-negative Breast Cancer: Preliminary Results of the PERCEPTION Study.
PMID 39477319 — cells, triple negative breast neoplasms, platelet count, blood, breast neoplasms, lymphocytes, lymphocytes, tumor-infiltrating, neoplasms, perception, neutrophils, biopsy, biomarkers, breast, cell count, blood cells, blood platelets, blood cell count
Anticancer Res20240
New-generation technologies for spatial tissue analysis, indispensable tools for deciphering intratumor heterogeneity in the development of antibody-drug conjugates and radio-immunoconjugates for cancer treatment.
PMID 38751472 — pharmaceutical preparations, neoplasms, rna, messenger, biomarkers, immunoconjugates, therapeutics, tissues
Transl Breast Cancer Res20237
Recommandations francophones pour la pratique clinique concernant la prise en charge des cancers du sein de Saint-Paul-de-Vence 2022-2023.
PMID 38061827 — breast neoplasms, neoplasms, breast
Bull Cancer20236
Multicenter Harmonization Study of Pan-Trk Immunohistochemistry for the Detection of NTRK3 Fusions.
PMID 37084942 — antibodies, pathology, research design, clone cells, laboratories, neoplasms, immunohistochemistry
Mod Pathol20235

Clinical Studies 7

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

N/A 4
Phase 2 3

By status:

Completed 3
Active not recruiting 2
Recruiting 1
Unknown 1

By type:

Interventional 4
Observational 3

By Monocentric/Multicentric:

monocentric 4
multicentric2to4 0
multicentric5to9 1
multicentricup10 2

Main Topics

Ongoing Clinical Trials

Ongoing trial started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Xenografts Development From Surgical Tumor Samples of Patients With Triple Negative or Luminal B Breast Cancer
NCT04133077 — serology, blood, breast neoplasms, neoplasms, breast, neoadjuvant therapy, therapeutics, heterografts, prospective studies, female
N/ARecruiting2021

LeadR Networks

Main global connection map